GlassScriptPhysician profile
Dipali S Patel
NPI 1629381652
$18,260.82
in general payments reported to CMS, 2019-2025
61 companies · $2,941 in 2025
The $2,941 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,564 · 2020: $703 · 2021: $2,158 · 2022: $3,864 · 2023: $3,937 · 2024: $3,094 · 2025: $2,941.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,946 · Education: $26.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,946.41 |
| Education | $26.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,164.51 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,762.29 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $1,331.94 | 2019-2025 | |
| Pfizer INC. | $1,331.23 | 2019-2025 | |
| Lilly USA, LLC | $1,229.12 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $1,065.88 | 2019-2025 | Repatha, Otezla, Otezla |
| Lucid Diagnostics INC. | $1,022.30 | 2022-2025 | |
| Gilead Sciences, INC. | $721.10 | 2019-2025 | |
| Glaxosmithkline, LLC. | $660.39 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Chugai Pharmaceutical Co., LTD. | $500.00 | 2022 | |
| Bausch Health US, LLC | $485.56 | 2023-2025 | Aplenzin |
| Amarin Pharma, INC. | $461.57 | 2019-2022 | |
| Exact Sciences Corporation | $399.25 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $385.98 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $313.88 | 2019-2025 |
Show all 61 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $306.29 | 2020-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $305.11 | 2021-2025 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $296.21 | 2019-2023 | Trintellix |
| Dynavax Technologies Corporation | $290.28 | 2023-2025 | Heplisav-B |
| Biohaven Pharmaceutical Holding Company LTD. | $275.05 | 2022 | |
| Novartis Pharmaceuticals Corporation | $260.90 | 2022-2025 | |
| Currax Pharmaceuticals LLC | $255.96 | 2021-2025 | Contrave, Nexletol, Nexlizet |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $255.50 | 2022-2025 | Xifaxan, Ibschek |
| Teva Pharmaceuticals USA, INC. | $204.06 | 2019-2022 | |
| Shield Therapeutics INC | $197.67 | 2023-2025 | Accrufer |
| Horizon Therapeutics Plc | $176.92 | 2021-2022 | |
| Noven Therapeutics, LLC | $169.26 | 2023-2025 | Xelstrym |
| Corium, LLC | $166.16 | 2022-2025 | Azstarys |
| Idorsia Pharmaceuticals US INC | $132.73 | 2022-2024 | Quviviq |
| Biohaven Pharmaceuticals, INC. | $106.26 | 2021 | |
| Merck Sharp & Dohme LLC | $99.21 | 2019-2024 | Gardasil, Capvaxive, Gardasil 9 |
| Allergan, INC. | $91.12 | 2019-2022 | |
| Antares Pharma, INC. | $79.12 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $66.53 | 2023 | |
| Genentech USA, INC. | $62.20 | 2021-2022 | |
| Genzyme Corporation | $60.00 | 2020 | |
| Upsher-Smith Laboratories LLC | $39.89 | 2022 | |
| Viiv Healthcare Company | $35.19 | 2024-2025 | Apretude |
| Azurity Pharmaceuticals, INC. | $31.82 | 2025 | Edarbi |
| Neos Therapeutics, LP | $31.59 | 2019-2022 | |
| Axsome Therapeutics, INC. | $28.93 | 2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $28.82 | 2025 | Fanapt |
| Kowa Pharmaceuticals America, INC. | $28.52 | 2021 | |
| Boston Scientific Corporation | $27.84 | 2025 | Watchman Access System |
| Cleerly, INC. | $27.00 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Vivus LLC | $26.96 | 2021-2024 | Qsymia |
| Eisai INC. | $25.14 | 2021 | |
| Neuronetics, INC. | $24.74 | 2025 | Neurostar Tms Therapy System |
| Alk-Abello, INC | $22.21 | 2025 | Neffy, Odactra, Grastek |
| Qiagen, LLC | $21.96 | 2022 | |
| Redhill Biopharma INC. | $20.45 | 2020 | |
| Jazz Pharmaceuticals INC. | $18.64 | 2021 | |
| Endo Pharmaceuticals INC. | $17.99 | 2019 | |
| Adlon Therapeutics L.P. | $17.58 | 2021 | |
| Ibsa Pharma INC. | $17.07 | 2019 | |
| Axonics, INC. | $15.91 | 2022 | |
| Fidia Pharma USA INC. | $14.42 | 2019 | |
| Arbor Pharmaceuticals, INC. | $14.13 | 2019 | |
| Phadia US INC. | $13.65 | 2022 | |
| Amneal Pharmaceuticals LLC | $11.77 | 2020 | |
| Penumbra, INC. | $7.06 | 2023 | Indigo System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dipali Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.